Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Daniel Lim

Sports Medicine Honolulu, HI Medical Doctor

NPI 1790121507 CMS profile 35460

1401 S Beretania St Ste 750, Honolulu, HI 96814

Open in the dashboard

General payments

$27,853

85 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Daniel Lim of Honolulu, HI is reported in the CMS Open Payments database as having received $27,853 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,600 20
2021 General $1,286 3
2020 General $164 1
2019 General $24,804 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Lim
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Daniel Lim were reported at $0. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Daniel Lim Sports Medicine median Middle half National median
2019 $24,804 $1,176 $199–$4,249 $163
2020 $164 $708 $96–$2,890 $114
2021 $1,286 $1,213 $152–$3,994 $132
2022 $1,600 $1,230 $159–$3,998 $149
2023 $0 $584 $146–$2,836 $160
2024 $0 $628 $163–$3,168 $164
2025 $0 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Arthrex, Inc. $16,503 49 payments
  2. Smith+Nephew, Inc. $2,992 5 payments
  3. Stryker Corporation $2,245 14 payments
  4. Micromed Inc $2,162 2 payments
  5. Djo, LLC $1,875 3 payments
  6. ImpactOrtho, Inc. $1,557 4 payments
  7. Advanced Orthopaedic Solutions, Inc. $164 1 payment
  8. Acumed LLC $127 1 payment
  9. DePuy Synthes Sales Inc. $75 1 payment
  10. Zimmer Biomet Holdings, Inc. $66 1 payment
  11. Other $88 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Education $19,037 14 payments
  2. Food and Beverage $3,780 55 payments
  3. Travel and Lodging $3,161 13 payments
  4. Grant $1,875 3 payments
Products named General payments · program years 2019–2022
  1. HIP ARTHROSCOPY ACCESS & INSTRUMENTATION SET $1,566 5 payments
  2. CINCHLOCK SS $616 8 payments
  3. Regeneten $200 3 payments
  4. MICRORAPTOR Knotless Anchor $173 2 payments
  5. AOS PRODUCTS $164 1 payment
  6. Q-FIX $143 1 payment
  7. Elbow Plating System $127 1 payment
  8. Anatomic Radial Head System $127 1 payment
  9. Clavicle Plating System $127 1 payment
  10. DYNACORD $75 1 payment
  11. Other $378 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

79

Median for Sports Medicine: 144

Drug cost

$794

Median for Sports Medicine: $1,027

Branded share of claims

0%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 16 $376
Naproxen Generic 17 $190
Oxycodone Hcl Generic 34 $159
Ibuprofen Generic 12 $68

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$101,327

Of which drugs: $6,810

Medicare patients

271

Average age 74

Services billed

2,706

145 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Chronic kidney disease 28%
Ischemic heart disease 21%
Osteoporosis 20%
Cancer 13%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 16 964 $4,966
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 550 $398

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record